Diclazepam

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Diclazepam
Diclazepam structure.svg
Diclazepam molecule ball.png
Clinical data
Routes of
administration
Oral, sublingual
Legal status
Legal status
Pharmacokinetic data
Bioavailability ?
Metabolism Hepatic
Biological half-life ~42 hours[1]
Excretion Renal
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C16H12Cl2N2O
Molar mass 319.185 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Diclazepam (Ro5-3448), also known as chlorodiazepam and 2'-chloro-diazepam, is a benzodiazepine and functional analog of diazepam. It was first synthesized by Leo Sternbach and his team at Hoffman-La Roche in 1960.[2] It is not currently approved for use as a medication, but rather sold as an unscheduled substance.[3][4] Efficacy and safety have not been tested in humans.

In animal models, its effects are similar to diazepam, possessing long-acting anxiolytic, anticonvulsant, hypnotic, sedative, skeletal muscle relaxant, and amnestic properties.[citation needed]

Metabolism[edit]

Metabolism of this compound has been assessed,[1] revealing diclazepam has an approximate elimination half-life of 42 hours and undergoes N-demethylation to delorazepam, which can be detected in urine for 6 days following administration of the parent compound.[5] Other metabolites detected were lorazepam and lormetazepam which were detectable in urine for 19 and 11 days, respectively, indicating hydroxylation by cytochrome P450 enzymes occurring concurrently with N-demethylation. The protein-binding of this compound has not been analysed but the figures for the metabolites are lorazepam 91.5% (parenterally) & 85% (orally)[6] and delorazepam >90%.[7]

Legal status[edit]

United Kingdom[edit]

In the UK, diclazepam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other benzodiazepine drugs.[8]

See also[edit]

References[edit]

  1. ^ a b Moosmann B, Bisel P, Auwärter V (July–August 2014). "Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics". Drug Testing and Analysis. 6 (7–8): 757–63. PMID 24604775. doi:10.1002/dta.1628. 
  2. ^ US 3136815, "Amino substituted benzophenone oximes and derivatives thereof" 
  3. ^ Madeleine Pettersson Bergstrand; Anders Helander; Therese Hansson; Olof Beck (2016). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. PMID 27366870. doi:10.1002/dta.2003. 
  4. ^ Høiseth, Gudrun; Tuv, Silja Skogstad; Karinen, Ritva (2016). "Blood concentrations of new designer benzodiazepines in forensic cases". Forensic Science International. 268: 35–38. PMID 27685473. doi:10.1016/j.forsciint.2016.09.006. 
  5. ^ Bareggi SR, Truci G, Leva S, Zecca L, Pirola R, Smirne S (1988). "Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans". European Journal of Clinical Pharmacology. 34 (1): 109–112. PMID 2896126. doi:10.1007/bf01061430. 
  6. ^ http://www.drugbank.ca/drugs/DB00186
  7. ^ http://www.drugbank.ca/drugs/DB01511
  8. ^ "The Misuse of Drugs Act 1971 (Amendment) Order 2017".